Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | KLKB1 | P03952 | 2/20 | 0.42 |
| ▸ | P2RX7 | Q99572 | 3/20 | 0.41 |
| ▸ | ROCK2 | O75116 | 5/20 | 0.40 |
| ▸ | ROCK1 | Q13464 | 5/20 | 0.40 |
| ▸ | MET | P08581 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.37 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22044115 | 0.84 | KLKB1 (0.43) | ATMSMN1; SMN2RAB9AKLKB1P2RX7 | |
| SCHEMBL22044032 | 0.83 | ATM (0.47) | ATMSMN1; SMN2RAB9AKLKB1P2RX7 | |
| SCHEMBL22044981 | 0.82 | KLKB1 (0.50) | ATMSMN1; SMN2RAB9AKLKB1P2RX7 | |
| SCHEMBL22044885 | 0.80 | ROCK2 (0.49) | ATMSMN1; SMN2RAB9AKLKB1P2RX7 | |
| SCHEMBL22044595 | 0.79 | ATM (0.48) | ATMSMN1; SMN2RAB9AKLKB1P2RX7 | |
| SCHEMBL22044097 | 0.79 | ATM (0.46) | ATMSMN1; SMN2RAB9AKLKB1P2RX7 | |
| SCHEMBL22044031 | 0.78 | ATM (0.47) | ATMSMN1; SMN2RAB9AKLKB1P2RX7 | |
| SCHEMBL22044154 | 0.75 | MET (0.41) | ATMRAB9AKLKB1P2RX7ROCK2 | |
| SCHEMBL22044160 | 0.74 | MET (0.42) | ATMRAB9AKLKB1P2RX7ROCK2 | |
| SCHEMBL22044048 | 0.73 | MAPK1 (0.48) | ATMKLKB1P2RX7ROCK2ROCK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200172521-A1 | Five-Membered-Fused-Six-Membered Aza-Aromatic Ring Compound, Preparation Method Thereof, Pharmaceutical Composition And Application Thereof | Amcure Biosciences Pte. Ltd. (SG) | 2020-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200172521-A1 | Five-Membered-Fused-Six-Membered Aza-Aromatic Ring Compound, Preparation Method Thereof, Pharmaceutical Composition And Application Thereof | KRAS, NRAS, RASSF5 | ATM 3850/4885SMN1; SMN2 4144/4885RAB9A 51/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.